Kalytera Therapeutics Inc (OTCMKTS:KALTF) today spoke in relation to its lead product development program. The company seeks to undertake an evaluation on cannabidiol (“CBD”).
It hopes to discover its role towards the treatment and the prevention of acute GVHD. This is a life-threatening condition that has so far claimed quite a significant number of lives globally. Experts say it usually occurs following a bone marrow transplant.
A closer outlook
The transplanted donor cells attack several body organs. These organs include the GI tract, eyes, lungs, liver and the skin. A patient struggling with GVHD may suffer from infections and chronic illnesses. Such patients may become disabled and even risk a reduced quality of life.
Acute GVHD is a serious condition, but a lot of people say the FDA hasn’t yet taken the matter with the seriousness it deserves. They think that it should by now have approved therapies to help with either the prevention or the treatment.
A lot of patients are opposed to the consumption of ingredients that cause them to encounter cognitive effects or euphoria. Kalytera is currently testing a CBD formulation that will help with the prevention of acute GVHD.
Kalytera is working on two development programs at the moment. The first one has to do with the evaluation of CBD and its role in helping prevent acute GVHD. The other one will pay focus to the evaluation of CBD in line with the treatment of acute GVHD.
Kalytera says that the prevention program is currently underway. It is on the second phase and patients have been handpicked from three clinical sites situated in Israel. After completing this phase, the business will be making preparations for the pivotal Phase 3 clinical study.
The CEO of Kalytera Robert Farrell says that they are working on top strategies that will help them boost their shareholder value. He believes the best way to go about it is by advancing this company’s programs in GVHD. He insists there is need to drive them to Phase 3 status.
Kalytera has also unveiled its grant of stock options to the various employees and directors as well.
Vapor Group Inc (OTCMKTS:VPOR) Business Model Paying Off As Orders for Isolate CBD Stream In
Vapor Group Inc (OTCMKTS:VPOR) is evidently having a spectacular run following the adoption of a new business model early this year focused on the lucrative CBD industry estimated to be worth well over $16 billion. The company recently secured $80,000 order for its premium CBD isolate bringing the total tally of orders to $600,000 this year alone.
$500,000 in under 3 months
As of April this year, the company had reportedly secured orders totaling about $500,000. In its Q1 2019 earnings, VPOR reported a number of high-profile business deals from reputable names in the industry including White Label liquid and GenCanna global, Inc among others. The company’s biggest purchase order thus far came in May when industry titan, Diamond CBD owned by potNetwork holdings placed a hefty $210,000 order for its bulk CBD isolate.
Vapor bills itself as the provider of industry grade CBD isolate famed for its high potency and purity. The product is developed in the company’s state-of-art manufacturing facilities that utilize sophisticated nanotechnology to deliver a premium end product sought after by industry leaders. The trickling enormous purchase orders are testimony of the product’s unparalleled effectiveness.
The company’s products are manufactured from 100% organic hemp sourced from the best growers in the United States from the states of Colorado, Kentucky, and Oregon. VPOR is constantly researching and experimenting on new processing methods and techniques to stay at par with the industry’s dynamic trends.
VPOR’s President and CEO, David Zinger is confident that the company is on course to becoming the premium suppliers of industry-level CBD isolate. Zinger credits the company’s success to over the past few months to “smart planning and strategizing.” Further, he is optimistic that with the continued sustainable growth, the will be able to provide long-term value to their stakeholders.
Positive trends witnessed in the CBD industry points to a lucrative future for players in the sector including Vapor. Reportedly, 7% of Americans are using CBD products now with the number expected to spike by 10% come 2025.
Medical Marijuana Inc. (OTCMKTS:MJNA) Authorized To Offer CBD Products In Bulgaria
Medical Marijuana Inc. (OTCMKTS:MJNA) has announced that it has been granted authorization to sell its hemp derived CBD products in Bulgaria.
Medical Marijuana receives authorization for CBD products in Bulgaria
Blake Schroeder the CEO of Kannaway stated that they are delighted to continue paving the way for CBD acceptance in Bulgaria to follow suit with what is happening in the rest of the world. The CEO added that following the authorization they were hoping to position themselves in the Bulgarian market and become leaders in CBD education across Europe.
The authorization means that Kannaway’s goods will be freely sold in Bulgaria and they are equally approved for export. Kannaway VP Alex Grapov said that the company was looking forward to trailblazing the global CBD market as advocates of its benefits. He added that they have met with regulatory bodies to makes sure that the company’s operations are within the purview of the law thus creating an avenue for customers and brand ambassadors.
Publication of CBD research on CIPN in Molecular Sciences Journal
Last week Medical Marijuana announced that its portfolio company Kannalife Inc. (OTCMKTS: KLFE) had published its findings on Chemotherapy-Induced Peripheral Neuropathy in the Molecular Neuroscience Journal. Market Study Report LLC has indicated that the international market for CIPN treatment is expected to exceed $1.88 billion by 2024. Kannalife expects clinical trials for its CBD-like molecule KLS-13019 as a therapeutic treatment for CIPN to commence in the second quarter of 2020.
Medical Marijuana CEO Stuart Titus said that CIPN affects around 30% to 405 of patients undergoing chemotherapy adding that they were pleased to support Kannalife in its research to discover a treatment alternative for such patients.
Kannalife was funded by the National Institute on Drug Abuse to work on the research. The grant permits the research in the development of KLS-13019 in CIPN and drug dependence. Kannalife has the obligation to study important advancements that involve identification of the mechanisms that bring CIPN and the application o0f study results in designing on novel treatment approaches for neuropathic pain and use of the approaches in reducing opioid prescription and opioid abuse.
Generex Biotechnology Corporation (OTCMKTS:GNBT) Launches An Integrated Health Management Platform
In a new wake of events, Generex Biotechnology Corporation (OTCMKTS:GNBT) has introduced a platform, which primarily deals with in-depth patient health management services. NuGenerex Medical Marketing (NMM) is a significant project and will act as the company’s sales and marketing backbone support. Some of the areas it will handle include patient identification, acquisition, and onboarding. Its establishment comes at a time when hundreds of pharmaceuticals businesses are seeking measures to accelerate their growth and expansion.
Generex is seeking entry into the U.S market and the reason it has embraced a multi-channel acquisition strategy. The strategy has been running for several months the main target being assets and organizations, which offer a series of services.
NMM will provide national marketing and customer service capabilities
Generex will benefit in a million ways from the new establishment; thanks to its capabilities. NMM plans to roll out an extensive pharmacy backbone, which will in return offer a nationwide footprint. It will have an integration with Customer Relationship Management (CRM) dashboard for Generex. Through a dedicated call-center, the integration will support the company’s ongoing patient support services and particularly the chronic care management.
In addition, NMM will offer compliant direct-to-patient outreach services, which are fully compliant with the market needs. An accomplished team, which has deep experience in pharmaceutical and medical device sales will support the new move. The team is trained in HIPAA, FTC and it has full exposure of the FDA rules. Thus it will ensure adherence to processes and procedures in the delivery of medical services.
The realization of a vision for a new healthcare enterprise
For the last two years, Generex has worked diligently to enhance the delivery of its services. Its emphasis is on unlocking new platforms, which will offer end-to-end treatment and services solutions. This far, the company is happy with its achievements according to the Chief Executive Officer Joseph Moscato.
He says, “We are delighted to launch NuGenerex Medical Marketing as another step in our overall corporate strategy to provide end-to-end solutions that optimize patient health outcomes.”
Meanwhile, the company has vowed to continue closing on the acquisition of additional operating assets. Its expectation is to meet the initial listing requirements one of them being a lucrative enterprise with a presence in another 23 states.
CBD and Rheumatoid Arthritis
What Works Best for Treating Pain with CBD Tincture, Soft gels or Creams? #CBD Tincture #Best All Organic CBD Cream
CBD and Depression Treatments
Can CBD cure Colitis and Crohns?
CBD and Chronic Pain Treatments
Benefits of Using CBD When Treating Cancer
BUSINESS1 year ago
Abattis Bioceuticals Corp (OTCMKTS:ATTBF) Unveils “Comfort” A New Product Line Targeting Chronic Pain & Inflammation
CBD CONDITIONS & TREATMENTS1 year ago
Addisons Disease and CBD Treatments
BENEFITS OF CBD1 year ago
Sickle Cell Anemia and CBD
BENEFITS OF CBD8 months ago
Why CBD is so Effective for Lupus
BENEFITS OF CBD8 months ago
CBD and Its Promise for Diabetes
BENEFITS OF CBD9 months ago
How Back Pain Has a New Enemy in CBD Oil
BENEFITS OF CBD7 months ago
CBD as a Key Player in the Fight Against Crohn’s Disease
BENEFITS OF CBD7 months ago
CBD as an Option for Psoriasis Sufferers